Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zofenoprilat is the active metabolite of the prodrug zofenopril, which is an angiotensin-converting enzyme (ACE) inhibitor. It competitively binds to and inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This inhibition prevents the potent vasoconstrictive actions of angiotensin II and results in vasodilation. Zofenoprilat also decreases angiotensin II-induced aldosterone secretion by the adrenal cortex, leading to increased sodium excretion and water outflow[5][2]. The drug is primarily used for its cardioprotective and antihypertensive effects in cardiovascular diseases such as hypertension and heart failure[6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zofenoprilat.